These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 21960080

  • 1. Evaluation of bone mineral density in Iranian HIV/AIDS patients.
    Badie BM, Soori T, Kheirandish P, Izadyar S, SeyedAlinagh S, Foroughi M, Rostamian A, Mohraz M.
    Acta Med Iran; 2011; 49(7):460-7. PubMed ID: 21960080
    [Abstract] [Full Text] [Related]

  • 2. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
    Guo FP, Yu XB, Luo L, Han Y, Qiu ZF, Zuo LY, Li YL, Yu W, Li TS.
    Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):649-52. PubMed ID: 20979781
    [Abstract] [Full Text] [Related]

  • 3. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors.
    Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, Mercié P, Morlat P, Thiébaut R, Dabis F, Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.
    AIDS; 2008 Jan 30; 22(3):395-402. PubMed ID: 18195566
    [Abstract] [Full Text] [Related]

  • 4. [Influence of long-term highly active antiretroviral therapy on bone mineral density in HIV/AIDS patients].
    Su YB, Xie J, Han Y, Qiu ZF, Li YL, Song XJ, Yu W, Li TS.
    Zhonghua Yi Xue Za Zhi; 2012 May 08; 92(17):1155-8. PubMed ID: 22883000
    [Abstract] [Full Text] [Related]

  • 5. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
    Madeddu G, Spanu A, Solinas P, Calia GM, Lovigu C, Chessa F, Mannazzu M, Falchi A, Mura MS, Madeddu G.
    Q J Nucl Med Mol Imaging; 2004 Mar 08; 48(1):39-48. PubMed ID: 15195003
    [Abstract] [Full Text] [Related]

  • 6. BMD is reduced in HIV-infected men irrespective of treatment.
    Amiel C, Ostertag A, Slama L, Baudoin C, N'Guyen T, Lajeunie E, Neit-Ngeilh L, Rozenbaum W, De Vernejoul MC.
    J Bone Miner Res; 2004 Mar 08; 19(3):402-9. PubMed ID: 15040828
    [Abstract] [Full Text] [Related]

  • 7. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).
    Bolland MJ, Grey A, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Gamble GD, Reid IR.
    Clin Endocrinol (Oxf); 2012 May 08; 76(5):643-8. PubMed ID: 22040002
    [Abstract] [Full Text] [Related]

  • 8. Potential predictive factors of osteoporosis in HIV-positive subjects.
    Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabò EV, Melzi S, Bini T, Sardanelli F, Cornalba G, Monforte Ad.
    Bone; 2006 Jun 08; 38(6):893-7. PubMed ID: 16377270
    [Abstract] [Full Text] [Related]

  • 9. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.
    Fernández-Rivera J, García R, Lozano F, Macías J, García-García JA, Mira JA, Corzo JE, Gómez-Mateos J, Rueda A, Sánchez-Burson J, Pineda JA.
    HIV Clin Trials; 2003 Jun 08; 4(5):337-46. PubMed ID: 14583850
    [Abstract] [Full Text] [Related]

  • 10. Serum leptin and bone metabolism in HIV patients treated with highly active antiretroviral therapy.
    Madeddu G, Spanu A, Chessa F, Calia GM, Lovigu C, Mannazzu M, Falchi A, Sanna D, Mura MS, Madeddu G.
    Q J Nucl Med Mol Imaging; 2009 Jun 08; 53(3):290-301. PubMed ID: 18596668
    [Abstract] [Full Text] [Related]

  • 11. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.
    Goh SSL, Lai PSM, Tan ATB, Ponnampalavanar S.
    Osteoporos Int; 2018 Mar 08; 29(3):595-613. PubMed ID: 29159533
    [Abstract] [Full Text] [Related]

  • 12. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.
    Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR.
    Clin Endocrinol (Oxf); 2007 Aug 08; 67(2):270-5. PubMed ID: 17547686
    [Abstract] [Full Text] [Related]

  • 13. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA.
    AIDS; 2007 Nov 30; 21(18):2473-82. PubMed ID: 18025884
    [Abstract] [Full Text] [Related]

  • 14. Valid treatment options for osteoporosis and osteopenia in HIV-infected persons.
    Clay PG, Voss LE, Williams C, Daume EC.
    Ann Pharmacother; 2008 May 30; 42(5):670-9. PubMed ID: 18413693
    [Abstract] [Full Text] [Related]

  • 15. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
    Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, Katlama C, Costagliola D, ANRS 121 Hippocampe study group.
    AIDS; 2009 Apr 27; 23(7):817-24. PubMed ID: 19363330
    [Abstract] [Full Text] [Related]

  • 16. Prevalence and predictors of osteopenia and osteoporosis in adults with Type 1 diabetes.
    Hamilton EJ, Rakic V, Davis WA, Chubb SA, Kamber N, Prince RL, Davis TM.
    Diabet Med; 2009 Jan 27; 26(1):45-52. PubMed ID: 19125760
    [Abstract] [Full Text] [Related]

  • 17. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy.
    Bruder JM, Ma JZ, Basler JW, Welch MD.
    Urology; 2006 Jan 27; 67(1):152-5. PubMed ID: 16413352
    [Abstract] [Full Text] [Related]

  • 18. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.
    Seminari E, Castagna A, Soldarini A, Galli L, Fusetti G, Dorigatti F, Hasson H, Danise A, Guffanti M, Lazzarin A, Rubinacci A.
    HIV Med; 2005 May 27; 6(3):145-50. PubMed ID: 15876279
    [Abstract] [Full Text] [Related]

  • 19. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia.
    Brown TT, Ruppe MD, Kassner R, Kumar P, Kehoe T, Dobs AS, Timpone J.
    J Clin Endocrinol Metab; 2004 Mar 27; 89(3):1200-6. PubMed ID: 15001610
    [Abstract] [Full Text] [Related]

  • 20. RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men.
    Gibellini D, Borderi M, De Crignis E, Cicola R, Vescini F, Caudarella R, Chiodo F, Re MC.
    J Med Virol; 2007 Oct 27; 79(10):1446-54. PubMed ID: 17705184
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.